NEU neuren pharmaceuticals limited

Obviously there is disagreement re the end point(s), which it...

  1. 6,557 Posts.
    lightbulb Created with Sketch. 1857
    Obviously there is disagreement re the end point(s), which it could be fairly said was not anticipated prior to the Type B meeting, nor post that meeting - emails were hinted to be the solution.

    That has not eventuated and has led to a Type C meeting. My main point of interest is why the disagreement?

    Why not stick to P2 successes - what are the alternatives?

    We certainly won't know prior to the meeting.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$14.20
Change
0.890(6.69%)
Mkt cap ! $1.761B
Open High Low Value Volume
$13.50 $14.26 $12.96 $9.111M 655.8K

Buyers (Bids)

No. Vol. Price($)
1 2000 $14.17
 

Sellers (Offers)

Price($) Vol. No.
$14.23 3278 1
View Market Depth
Last trade - 16.15pm 27/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.